Anatara Lifesciences Ltd (AU:ANR) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Anatara Lifesciences has paused recruitment for its GaRP-IBS clinical trial after exceeding participant targets, with results expected in March 2025. The company is also offering a Share Purchase Plan to raise funds for this trial and an anti-obesity project. This strategic move could intrigue investors interested in the biotech sector as it positions the company for upcoming developments.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.